Endocrine Abstracts

Objectives: To evaluate the different insulin regimens and types of insulin used in our population of type 1 diabetes (DM1) patients in the last revision in our clinic.Method: A descriptive study was carried out in our population of 535 DM1 patients. They had their initial diagnosis between 1967 and 2014.Results: In our population, 47.3% were women and 52.3% were men. The mean age of our patients was 33.8 years (S.D....

Introduction: The European Society of Endocrinology Clinical Practice Guideline defines follow-up recommendations for AI based on the 1 mg overnight dexamethasone suppression test and the presence of associated comorbidities. Follow-up is not recommended for AI presenting serum cortisol levels post dexamethasone ≤1.8 μg/dl neither those presenting serum cortisol levels post dexamethasone between 1.9–5 μg/dl (defined as ‘possible autonomous cortisol se...

IntroductionDyslipidemia is a major cardiovascular risk factor, being its detection and control essential due to risk of serious complications. Numerous trials have demonstrated its relationship with T2D, but it has not been so well studied in T1D.ObjectiveTo obtain information about relationship between dyslipidemia and T1D and analyze its prevalence and control in a sample of patients.<p class="abstext"...

Introduction: Controversy exists regarding type 2 diabetes (T2D) remission rates after bariatric surgery (BS) due to heterogeneity in its definition and patients’ baseline features. We evaluate T2D remission using recent criteria, according to preoperative characteristics and insulin use.Materials and methods: Retrospective study from a cohort of 657 BS performed in a single centre (2006–2011) of which 141 (57.4% women) had T2D. Evaluation of a...

Introduction: Remission of type 2 diabetes (T2D) is a yearned outcome after bariatric surgery (BS). Attention to individuals who do not strictly fulfil remission criteria has been frequently left behind. The aim of this study was to evaluate metabolic control status in patients considered as diabetes ‘non-remitters’.Materials and methods: Retrospective study of 125 patients (59.2% women) with preoperative diagnosis of T2D who underwent BS in a ...

Introduction and objectives: The treatment with monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) is a new group of drugs that allows us to reach the therapeutic targets of low density cholesterol (LDL-c) in patients intolerant to statins or those who despite treatment with maximum doses of them do not obtain a proper lipid control.Material and methods: We performed a descriptive observational study. We include all ...

Introduction: New long-acting insulin analogues (insulin degludec –ID- and insulin glargine 300 U/ml –IG300-) have proved, in clinical trials, that improve metabolic control with lower hypoglycemia rate in T2D.Objective: To assess characteristics of T2D patients who were given ID and IG300 and to evaluate their effect on metabolic control, weight and insulin dose.Material and methods: We studied T2D patients whose treatme...